We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

53 hedge funds and large institutions have $20.6M invested in Theriva Biologics in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

7% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 15

25% less capital invested

Capital invested by funds: $27.4M → $20.6M (-$6.78M)

28% less funds holding

Funds holding: 74 → 53 (-21)

78% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 27

Holders
53
Holders Change
-21
Holders Change %
-28.38%
% of All Funds
1.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
14
Reduced
15
Closed
27
Calls
$5.91M
Puts
–
Net Calls
+$5.91M
Net Calls Change
-$682K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$633K
2
Millennium Management
Millennium Management
New York
+$523K
3
ECM
Element Capital Management
New York
+$274K
4
PP
Paloma Partners
Connecticut
+$209K
5
LP
LMR Partners
United Kingdom
+$194K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.52M
2
SM
Sabby Management
Florida
-$712K
3
State Street
State Street
Massachusetts
-$513K
4
Northern Trust
Northern Trust
Illinois
-$478K
5
BCM
Bridgeway Capital Management
Texas
-$228K
Name Holding Trade Value Shares
Change 		Change in
Stake
California Public Employees Retirement System
26
California Public Employees Retirement System
California
$57K – – –
SAM
27
Scopus Asset Management
New York
$57K – – –
Bank of New York Mellon
28
Bank of New York Mellon
New York
$41K -$110K -22 -73%
Squarepoint
29
Squarepoint
New York
$40K +$34.9K +7 +700%
BA
30
Bard Associates
Illinois
$37K – – –
WS
31
Wedbush Securities
California
$35K +$4.98K +1 +17%
VKH
32
Virtu KCG Holdings
New York
$34K -$14.9K -3 -30%
HighTower Advisors
33
HighTower Advisors
Illinois
$32K +$9.96K +2 +40%
State Street
34
State Street
Massachusetts
$31K -$513K -103 -94%
FSA
35
Franklin Street Advisors
North Carolina
$29K -$39.8K -8 -57%
SFSIG
36
San Francisco Sentry Investment Group
California
$23K +$9.96K +2 +67%
OAM
37
Oxford Asset Management
United Kingdom
$23K +$24.9K +5 New
TRCT
38
Tower Research Capital (TRC)
New York
$13K -$54.8K -11 -79%
HLA
39
Hamilton Lane Advisors
Pennsylvania
$13K – – –
MWM
40
Mission Wealth Management
California
$13K – – –
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
$12K – – –
CBA
42
Coastal Bridge Advisors
Connecticut
$11K +$4.98K +1 +100%
Bank of America
43
Bank of America
North Carolina
$9K -$9.96K -2 -50%
GC
44
Guggenheim Capital
Illinois
$8K – – –
PAG
45
Private Advisor Group
New Jersey
$8K – – –
Commonwealth Equity Services
46
Commonwealth Equity Services
Massachusetts
$8K +$4.98K +1 +100%
NCCM
47
Nine Chapters Capital Management
New Jersey
$7K +$4.98K +1 New
CAN
48
Cetera Advisor Networks
California
$6K – – –
PCM
49
Prelude Capital Management
New York
$6K +$4.98K +1 New
IP
50
Intellectus Partners
California
$5K – – –
1
2
3 4

TOVX Hedge Fund Activity: Q2 2017 in Review

53 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2017, worth a combined $20.6M — down 25% from $27.4M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of TOVX and 6 opened new positions — a net loss of 21 holders — while 15 trimmed existing stakes and 14 added.

The largest buyer was Goldman Sachs, adding an estimated $633K. The largest seller was BlackRock, cutting an estimated $2.52M.

  • 53 institutional investors held Theriva Biologics (TOVX) as of Q2 2017, down from 74 in Q1 2017.
  • Funds reported $20.6M of Theriva Biologics stock for Q2 2017, down 25% quarter-over-quarter.
  • 6 funds opened new Theriva Biologics positions in Q2 2017 and 27 closed out, a net change of -21 holders.
  • The largest Theriva Biologics buyer in Q2 2017 was Goldman Sachs, an estimated $633K added.
  • The largest Theriva Biologics seller in Q2 2017 was BlackRock, an estimated $2.52M sold.

Based on aggregated 13F filings for Q2 2017.